Study of Immune Checkpoint Inhibition with Chemotherapy in Treatment-Na ve Metastatic Anal Cancer Patients
Enrolling By Invitation
18-99 years
All
Phase
N/A
4 participants needed
1 Location
Brief description of study
This trial compares the addition of nivolumab to chemotherapy (carboplatin and paclitaxel) versus usual treatment (chemotherapy alone) for the treatment of anal cancer that has spread to other places in the body (metastatic). Chemotherapy drugs, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving nivolumab together with carboplatin and paclitaxel may help doctors find out if the treatment is better or the same as the usual approach.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Metastatic Anal Cancer
-
Age: Between 18 Years - 99 Years
-
Gender: All
Male or Female, Age 18 or older, Patient must have inoperable, recurrent, or metastatic disease not amenable to curative therapy Patient must have histological or cytological confirmation of anal squamous cell carcinoma from the primary tumor or a newly diagnosed recurrent/metastatic lesion
Updated on
01 Aug 2024.
Study ID: 850702
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For cancer trials contact EmergingMed: 1-855-216-0098 or PennCancerTrials@emergingmend.com
